Core Scientific (NASDAQ:CORZ) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Core Scientific (NASDAQ:CORZ) from a neutral rating to a buy rating in a research note released on Tuesday morning, Marketbeat reports. The firm currently has $25.00 target price on the stock. HC Wainwright also issued estimates for Core Scientific’s Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.60) EPS and FY2026 earnings at $0.16 EPS.

CORZ has been the topic of several other research reports. Macquarie lifted their target price on shares of Core Scientific from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, September 29th. Cantor Fitzgerald raised their price target on shares of Core Scientific from $18.00 to $26.00 and gave the stock an “overweight” rating in a research note on Friday, October 24th. Craig Hallum cut shares of Core Scientific from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 7th. UBS Group set a $30.00 price objective on shares of Core Scientific in a report on Wednesday, October 22nd. Finally, Barclays cut Core Scientific to an “underweight” rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $21.25.

Core Scientific Trading Down 0.1%

NASDAQ:CORZ opened at $20.74 on Tuesday. The stock has a 50 day moving average of $16.92 and a two-hundred day moving average of $13.68. Core Scientific has a 12 month low of $6.20 and a 12 month high of $22.12. The firm has a market cap of $6.43 billion, a P/E ratio of 138.28 and a beta of 6.58.

Core Scientific (NASDAQ:CORZ) last released its earnings results on Friday, October 24th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.39. The firm had revenue of $81.10 million during the quarter, compared to analysts’ expectations of $107.18 million. On average, research analysts forecast that Core Scientific will post 0.52 earnings per share for the current year.

Institutional Trading of Core Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the company. Oppenheimer Asset Management Inc. raised its position in shares of Core Scientific by 229.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 37,501 shares of the company’s stock valued at $272,000 after buying an additional 26,135 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Core Scientific during the first quarter worth $50,000. KBC Group NV raised its position in Core Scientific by 34.7% in the first quarter. KBC Group NV now owns 10,887 shares of the company’s stock valued at $79,000 after purchasing an additional 2,805 shares during the period. Vontobel Holding Ltd. raised its position in Core Scientific by 46.7% in the first quarter. Vontobel Holding Ltd. now owns 65,366 shares of the company’s stock valued at $473,000 after purchasing an additional 20,800 shares during the period. Finally, Summit Trail Advisors LLC acquired a new position in shares of Core Scientific in the 1st quarter valued at $357,000.

About Core Scientific

Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.